Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirotinib
- Development stage
- Unknown
- Lead developer
- Xuanzhu Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sirotinib (also known as XZP-5491) is an investigational, small-molecule, irreversible pan-HER (ErbB) receptor tyrosine kinase inhibitor developed by Xuanzhu Biopharmaceutical, a subsidiary of Sihuan Pharmaceutical. It is designed to target the epidermal growth factor receptor (EGFR/ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). Preclinical studies have demonstrated that sirotinib has broad-spectrum antitumor activity and is capable of crossing the blood-brain barrier. It is being evaluated in Phase 1 clinical trials in China for the treatment of advanced solid tumors, including non-small cell lung cancer, esophageal cancer, and gastric cancer.
- Other names
- sirotinib maleate赛罗替尼马来酸赛罗替尼
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on sirotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirotinib.